As Cann Group CEO, Peter brings more than 30 years of general management, marketing and commercial leadership roles within global pharmaceutical companies.
He has most recently been Head of Asia Pacific for French biopharmaceutical company, Ipsen, where he developed and led the implementation of a successful growth strategy which included the commercial launch of new brands. Previous roles include General Manager of Australia/New Zealand (Ipsen) and senior management positions with Astra/Zeneca, UK and Bristol-Myers Squibb in Europe.
Peter was appointed chair of Medicinal Cannabis Industry Australia (MCIA), Australia’s peak industry organisation, in November 2023.
He has a bachelor’s degree in science (pharmacology, immunology) and a diploma in education (science, biology) from Monash University and is a graduate of the INSEAD CEDEP General Management Program.